For individuals living with Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a debilitating condition, the introduction of this treatment and Tafamidis meglumine represents a true change. These groundbreaking therapies protect the transthyretin protein, halting its harmful build-up and reducing the severity of the disease . Individuals are now seein